Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma

NCT01108458 is registered in ClinicalTrials.gov with George Albert Fisher as lead sponsor.

NCT NCT01108458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01108458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
Lead sponsor
George Albert Fisher
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2010
Completion date
March 31, 2011
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer